Monopar Therapeutics Inc (MNPR) concluded trading on Thursday at a closing price of $32.66, with 19.49 million shares of worth about $636.54 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 940.96% during that period and on October 24, 2024 the price saw a gain of about 605.40%. Currently the company’s common shares owned by public are about 2.98M shares, out of which, 1.76M shares are available for trading.
Stock saw a price change of 471.98% in past 5 days and over the past one month there was a price change of 531.72%. Year-to-date (YTD), MNPR shares are showing a performance of 1820.05% which increased to 1299.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.37 but also hit the highest price of $8.65 during that period. The average intraday trading volume for Monopar Therapeutics Inc shares is 812.93K. The stock is currently trading 389.03% above its 20-day simple moving average (SMA20), while that difference is up 613.44% for SMA50 and it goes to 800.84% higher than SMA200.
Monopar Therapeutics Inc (NASDAQ: MNPR) currently have 2.98M outstanding shares and institutions hold larger chunk of about 2.16% of that.
The stock has a current market capitalization of $114.96M and its 3Y-monthly beta is at 1.27. It has posted earnings per share of -$2.30 in the same period. It has Quick Ratio of 6.59 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MNPR, volatility over the week remained 146.71% while standing at 44.48% over the month.
Stock’s fiscal year EPS is expected to drop by -86.15% while it is estimated to decrease by -20.18% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on October 11, 2024 offering a Buy rating for the stock and assigned a target price of $50 to it. Coverage by ROTH Capital stated Monopar Therapeutics Inc (MNPR) stock as a Buy in their note to investors on January 28, 2021, suggesting a price target of $49 for the stock.
